Can a Slow-Release chemo implant tackle an untreatable brain tumor?

NCT ID NCT07767110

NEW Not yet recruiting ⭐️ CURE ⭐️ Sponsor: NanOlogy, LLC Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial is testing whether a new formulation of the chemotherapy drug cisplatin, called LSAM-Cisplatin, can be safely infused directly into the brain tumors of children and young adults with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The treatment is given as a single infusion during a surgical procedure guided by real-time MRI. The study aims to find the safest dose and to see if the drug can shrink the tumor or slow its growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LSAM-Cisplatin, a slow-release form of the chemotherapy drug cisplatin, given as a single infusion directly into the tumor during MRI-guided surgery
What this could lead to
If it works, this approach could offer a new treatment option for a type of brain tumor that is currently very hard to treat, potentially improving outcomes for children and young adults.
What could go wrong
This is an early-phase trial with a small number of participants, so the treatment may not be effective or may cause significant side effects. The study is primarily designed to test safety, not to prove benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.